Matson (NYSE:MATX) reported quarterly earnings of $6.53 per share which beat the analyst consensus estimate of $5.22 by 25.1 percent. This is a 300.61 percent increase over earnings of $1.63 per share from the same period last year. The company reported quarterly sales of $1.07 billion which beat the analyst consensus estimate of $991.25 million by 8.15 percent. This is a 66.15 percent increase over sales of $645.20 million the same period last year.
Matson Q3 EPS $6.53 Beats $5.22 Estimate, Sales $1.07B Beat $991.25M Estimate
Matson (NYSE:MATX) reported quarterly earnings of $6.53 per share which beat the analyst consensus estimate of $5.22 by 25.1 percent. This is a 300.61 percent increase over earnings of $1.63 per share from the same
Related Posts
Hawkins Insights: Return On Capital Employed
Looking at Q4, Hawkins (NASDAQ:HWKN) earned $12.88 million, a 22.75% increase from the preceding quarter. Hawkins also posted a total of $162.97 million in sales, a 14.02% increase since Q3. In Q3, Hawkins earned $10.49 million, and total sales reached $142.93 million.
Who Will Win The 2022 World Cup? Video Game That Predicted Last 2 Winners Says This Country
The 2022 FIFA World Cup is set to begin this week, with matches kicking off on Nov. 20, 2022. A total of 32 teams will play through a group stage and bracket style tournament to crown a winner.
Gilead’s Kite Announced Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis at ASH 2022
Kite, a Gilead Company (Nasdaq: GILD), today announced results from one of the largest real-world analyses of patients who received CAR T-cell therapy assessing the impact of time from leukapheresis to infusion ("vein-to-vein" time) for Yescarta® (axicabtagene ciloleucel) in adult patients with relapsed or refractory (R/R